NCT04982029View on ClinicalTrials.gov

Cannabidiol on Reward- and Stress-related Neurocognitive Processes in Individuals With Opioid Use Disorder

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

April 14, 2022

Primary Completion Date

December 2, 2022

Study Completion Date

December 2, 2022

Conditions
Opioid-use Disorder
Interventions
DRUG

Cannabidiol 100 MG/ML [Epidiolex]

600mg

DRUG

Placebo

Matching placebo

Trial Locations (2)

02115

Brigham and Women's Hospital, Boston

05701

Rutland Medical Center, Rutland

All Listed Sponsors
collaborator

Harvard Medical School (HMS and HSDM)

OTHER

lead

Brigham and Women's Hospital

OTHER